Marion Mccourt net worth and biography

Marion Mccourt Biography and Net Worth

Marion McCourt joined Regeneron in 2018 and serves as Executive Vice President and Head of the Commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Ms. McCourt began her career and spent 12 year at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.

What is Marion Mccourt's net worth?

The estimated net worth of Marion Mccourt is at least $14.46 million as of November 4th, 2022. Ms. Mccourt owns 19,644 shares of Regeneron Pharmaceuticals stock worth more than $14,462,502 as of November 25th. This net worth estimate does not reflect any other investments that Ms. Mccourt may own. Learn More about Marion Mccourt's net worth.

How do I contact Marion Mccourt?

The corporate mailing address for Ms. Mccourt and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected] Learn More on Marion Mccourt's contact information.

Has Marion Mccourt been buying or selling shares of Regeneron Pharmaceuticals?

Over the course of the past ninety days, Marion Mccourt has sold $1,503,749.00 of Regeneron Pharmaceuticals stock. Most recently, Marion Mccourt sold 1,000 shares of the business's stock in a transaction on Friday, November 4th. The shares were sold at an average price of $727.82, for a transaction totalling $727,820.00. Following the completion of the sale, the executive vice president now directly owns 19,644 shares of the company's stock, valued at $14,297,296.08. Learn More on Marion Mccourt's trading history.

Who are Regeneron Pharmaceuticals' active insiders?

Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Regeneron Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 44 times. They sold a total of 142,306 shares worth more than $94,657,219.74. The most recent insider tranaction occured on November, 23rd when EVP Plew Daniel P Van sold 11,972 shares worth more than $8,868,259.00. Insiders at Regeneron Pharmaceuticals own 9.0 % of the company. Learn More about insider trades at Regeneron Pharmaceuticals.

Information on this page was last updated on 11/23/2022.

Marion Mccourt Insider Trading History at Regeneron Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2022Sell1,000$727.82$727,820.0019,644View SEC Filing Icon  
10/3/2022Sell1,100$705.39$775,929.0019,644View SEC Filing Icon  
8/1/2022Sell1,100$581.53$639,683.0019,644View SEC Filing Icon  
7/1/2022Sell1,100$587.76$646,536.0019,644View SEC Filing Icon  
5/2/2022Sell1,100$656.97$722,667.0019,644View SEC Filing Icon  
4/1/2022Sell1,000$701.82$701,820.0022,014View SEC Filing Icon  
2/1/2022Sell1,000$607.46$607,460.00View SEC Filing Icon  
12/13/2021Sell344$653.12$224,673.28View SEC Filing Icon  
12/1/2021Sell1,000$639.13$639,130.00View SEC Filing Icon  
10/1/2021Sell1,000$576.75$576,750.00View SEC Filing Icon  
8/2/2021Sell1,000$577.12$577,120.0018,038View SEC Filing Icon  
5/7/2021Sell1,000$495.63$495,630.0018,038View SEC Filing Icon  
10/5/2020Sell1,000$600.00$600,000.0014,963View SEC Filing Icon  
See Full Table

Marion Mccourt Buying and Selling Activity at Regeneron Pharmaceuticals

This chart shows Marion Mccourt's buying and selling at Regeneron Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $736.23
Low: $728.61
High: $737.24

50 Day Range

MA: $727.99
Low: $684.63
High: $759.91

2 Week Range

Now: $736.23
Low: $538.01
High: $769.63

Volume

229,209 shs

Average Volume

639,110 shs

Market Capitalization

$80.18 billion

P/E Ratio

15.52

Dividend Yield

N/A

Beta

0.2